SCA
IPXL

SAC Capital Advisors’s Impax Laboratories, Inc. IPXL Stock Holding History

SAC Capital Advisors’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-63,998
Closed -$1.69M – 1359
2014
Q1 		$1.69M Buy
63,998
+46,524
+266% +$1.16M 0.01% 792
2013
Q4 		$439K Sell
17,474
-160,081
-90% -$3.57M ﹤0.01% 1227
2013
Q3 		$3.64M Buy
177,555
+48,355
+37% +$998K 0.02% 600
2013
Q2 		$2.58M Buy
+129,200
New +$2.29M 0.01% 694

Other funds holding IPXL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

SAC Capital Advisors's IPXL Position: Q2 2014 in Review

SAC Capital Advisors sold out of Impax Laboratories, Inc. (IPXL) in Q2 2014, closing a stake of 63,998 shares — an estimated $1.69M sold.

SAC Capital Advisors first reported a position in IPXL in Q2 2013 and held it in 4 quarters. The position peaked at $3.64M in Q3 2013. 185 funds tracked by Wall St. Rank hold IPXL as of Q2 2014.

  • SAC Capital Advisors reported no remaining Impax Laboratories, Inc. position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 63,998 Impax Laboratories, Inc. shares in Q2 2014, an estimated $1.69M.
  • SAC Capital Advisors first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 4 quarters.
  • SAC Capital Advisors's Impax Laboratories, Inc. position peaked at $3.64M in Q3 2013.
  • 185 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.